- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06096116
Phase-3-Studie zur Wirksamkeit und Sicherheit von aus menschlichem Plasma gewonnenem Antithrombin (Atenativ) bei Heparin-resistenten Patienten, bei denen eine Herzoperation geplant ist, die einen kardiopulmonalen Bypass erfordert
Phase 3, doppelblinde, placebokontrollierte, multizentrische Studie zur Wirksamkeit und Sicherheit von aus menschlichem Plasma gewonnenem Antithrombin (Atenativ) bei Heparin-resistenten Patienten, bei denen eine Herzoperation geplant ist, die einen kardiopulmonalen Bypass erfordert
The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Cristina Solomon, MD
- Telefonnummer: +41 79 585 90 42
- E-Mail: Cristina.Solomon@octapharma.com
Studienorte
-
-
-
Reims, Frankreich
- Beendet
- CHU de Reims, Hôpital Robert Debré
-
Rennes, Frankreich
- Zurückgezogen
- CHU de Rennes
-
-
-
-
British Columbia
-
New Westminster, British Columbia, Kanada, V3L0A4
- Rekrutierung
- Royal Columbian Hospital
-
-
Ontario
-
Kingston, Ontario, Kanada, K7L2V7
- Rekrutierung
- Kingston Health Sciences Centre
-
Toronto, Ontario, Kanada, M5G2C4
- Noch keine Rekrutierung
- Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, Kanada, H1T1C8
- Rekrutierung
- Montreal Heart Institute
-
-
-
-
-
Kaunas, Litauen
- Beendet
- Hospital of Lithuanian university of Health sciences Kauno Klinikos
-
Vilnius, Litauen
- Rekrutierung
- Vilnius University hospital Santaros Klinikos
-
-
-
-
-
Bucharest, Rumänien
- Rekrutierung
- Institute for Cardiovascular Diseases C.C. Iliescu
-
-
-
-
-
Kamenitz, Serbien
- Rekrutierung
- Institute of Cardiovascular Diseases Vojvodina
-
-
-
-
-
Ljubljana, Slowenien
- Rekrutierung
- University Medical Centre Ljubljana
-
-
-
-
-
Brno, Tschechien
- Rekrutierung
- Center of Cardiovascular and Transplant Surgery
-
Prague, Tschechien
- Beendet
- Institute for Clinical and Experimental Medicine
-
-
-
-
California
-
Stanford, California, Vereinigte Staaten, 94305-5101
- Rekrutierung
- Stanford University School of Medicine
-
-
Florida
-
Miami, Florida, Vereinigte Staaten, 33136
- Rekrutierung
- University of Miami
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Rekrutierung
- Massachusetts General Hospital
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710-1000
- Rekrutierung
- Duke University Medical Center
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Rekrutierung
- Atrium Health Wake Forest Baptist
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- Cleveland Clinic
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Rekrutierung
- The Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- OU Health University of Oklahoma Medical Center
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390
- Rekrutierung
- University of Texas Southwestern Medical Center
-
-
-
-
-
Cambridge, Vereinigtes Königreich
- Rekrutierung
- Royal Papworth Hospital
-
Coventry, Vereinigtes Königreich
- Rekrutierung
- University Hospital Coventry and Warwickshire
-
Middlesbrough, Vereinigtes Königreich
- Rekrutierung
- The James Cook University Hospital
-
-
-
-
-
Innsbruck, Österreich
- Rekrutierung
- University Hospital Innsbruck
-
Vienna, Österreich
- Rekrutierung
- Vienna General Hospital AKH, Medical University of Vienna
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Planned cardiac surgery with CPB
- Heparin-resistant patients (pre-CPB Hemochron ACT less than 480 s in the measurement taken between 2-5 minutes following intravenous administration of 500 U/kg UFH)
- Patients between 18 and 85 years of age, inclusive
- Freely given written or electronic informed consent
- In female patients of childbearing potential, a pre-existing negative pregnancy test within 14 days prior to surgery
Exclusion Criteria:
-
Receiving, or have received within the timeframes specified, one or more of the following medications prior to the start of surgery:
- vitamin K antagonists (within 3 days)
- direct oral anticoagulants (within 2 days)
- thienopyridines (ticlopidine within 14 days, prasugrel within 7 days, or clopidogrel within 5 days), unless platelet function is satisfactory according to local standard of care assessment
- ticagrelor (within 5 days), unless platelet function is satisfactory according to local standard of care assessment
- glycoprotein IIb/IIIa antagonist (within 24 hours)
-
Pre-existing coagulopathy, a history of bleeding problems, or a laboratory-diagnosed bleeding disorder (e.g., von Willebrand disease, platelet disorder)
-
Renal insufficiency, defined as serum creatinine level >2.0 mg/dL
-
Thrombocytosis, defined as platelet count >400,000 per μL
-
Known hypersensitivity or allergic reaction to antithrombin or any of the excipients in Atenativ, i.e., human albumin, sodium chloride, acetyl tryptophan, caprylic acid
-
History of anaphylactic reaction(s) to blood or blood components
-
Refusal to receive transfusion of blood or blood-derived products
-
Current participation in another interventional clinical trial or previous participation in the current trial
-
Treatment with any IMP within 30 days prior to screening visit
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Low-dose Atenativ
Patients will receive a single bolus of 30 international units (IU)/kg body weight (BW) Atenativ. |
A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma |
|
Experimental: High-dose Atenativ
Patients will receive a single bolus of 60 international units (IU)/kg body weight (BW) Atenativ. |
A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma |
|
Placebo-Komparator: Placebo
Patients will receive a saline bolus dose |
Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Restoring heparin responsiveness
Zeitfenster: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The percentage of patients in each group in whom no further therapy containing antithrombin (i.e. frozen plasma or other antithrombin concentrates) is needed for restoring pre-CPB heparin responsiveness after administration of Atenativ or placebo, and for maintaining it during CPB |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Amounts of further therapy for restoring heparin responsiveness
Zeitfenster: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The comparison between the amounts of further therapy containing antithrombin (i.e., FP or antithrombin concentrates) needed for restoring pre-CPB heparin responsiveness, after administration of Atenativ or placebo, and for maintaining it during CPB |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
|
Change in activated clotting time (ACT) values
Zeitfenster: Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion
|
The comparison between the change in ACT values following infusion of each of the Atenativ doses and placebo |
Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion
|
|
Change in antithrombin plasma levels
Zeitfenster: Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion
|
The comparison between the change in antithrombin plasma levels following infusion of each of the Atenativ doses and placebo |
Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion
|
|
Change in heparin usage
Zeitfenster: From end of IMP infusion to the end of surgery
|
The comparison between heparin usage following the infusion of each of the Atenativ doses and infusion of placebo |
From end of IMP infusion to the end of surgery
|
|
FP unit use
Zeitfenster: From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first
|
The comparison between the number of units of FP transfused for reasons other than restoring or maintaining heparin responsiveness, both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first
|
|
Amounts of further antithrombin concentrate for maintaining heparin responsiveness
Zeitfenster: From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first
|
The comparison between postoperative use of antithrombin concentrates for reasons other than restoring heparin responsiveness (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first) |
From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first
|
|
Transfusion of allogenic blood products
Zeitfenster: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between transfusion of other allogeneic blood products (e.g., red blood cells [RBCs], platelets, cryoprecipitate, whole blood, albumin, other transfusion), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Administration of coagulation factor concentrates
Zeitfenster: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between administration of coagulation factor concentrates (fibrinogen concentrate, factor XIII concentrate, recombinant activated factor VII, other therapy)", both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Administration of other haemostatic-relevant therapies
Zeitfenster: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between administration of other haemostatic-relevant therapies (i.e., tranexamic acid, aminocaproic acid, protamine, other therapies), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Postoperative chest tube drainage
Zeitfenster: From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between postoperative chest tube drainage volume at 24 hours after the start of Atenativ or placebo infusion, and the comparison between total chest tube drainage volume until discharge or 7 days after surgery, whichever comes first |
From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Need for reoperation due to bleeding
Zeitfenster: 24 hours after the start of IMP infusion
|
Comparison of the need for reoperation for bleeding, including description of the cause of bleeding (surgical vs. non-surgical) |
24 hours after the start of IMP infusion
|
|
Cell saver volume
Zeitfenster: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The comparison between cell saver volume until the end of surgery |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
|
Adverse events
Zeitfenster: From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first
|
Incidence of adverse events, including all related and non-related, non-serious adverse events |
From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first
|
|
Serious adverse events
Zeitfenster: From the start of IMP infusion until 28 days after IMP administration
|
Incidence of serious adverse events |
From the start of IMP infusion until 28 days after IMP administration
|
|
Survival status
Zeitfenster: At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration
|
Number of patients surviving in all three cohorts |
At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration
|
|
Red Blood Cell count
Zeitfenster: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
White Blood Cell count
Zeitfenster: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
Haemoglobin levels
Zeitfenster: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
Haematocrit
Zeitfenster: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
|
Platelet count
Zeitfenster: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- ATN-108
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .